Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm watching a 1 minute chart. The 20 day sma is creeping up. Right now it's at 4.07. I think she's getting ready to go again.
Almost 1 mil in volume in 10 minutes. Wow! And this is a stock with only 11.1 mil float.
I'm in also. Go APRI
Edited. APRI-Apricus Biosciences, Inc. Very nice chart. Apricus Bioscience Inc
APRI.O
$3.84
+0.41+11.95%12:00am EST
Wed Dec 22, 2010 3:02pm EST
* Licenses Italian rights of Vitaros to Bracco SpA
* To get 5.5 million euros as upfront payment
* Apricus shares up 8 pct
Dec 22 (Reuters) - Apricus Biosciences Inc (APRI.O) said it licensed the Italian marketing rights of its experimental erectile dysfunction drug to Bracco SpA for an upfront payment of 5.5 million euro ($7.20 million).
Under the deal, Bracco gets the rights to commercialize and market the drug Vitaros under the Bracco trademark in Italy.
Apricus, which uses its drug delivery technology to administer drugs through the skin, will also be eligible to get double-digit royalties based on sales of the product.
The application for approval to market Vitaros in Europe is scheduled to be filed in April 2011, Apricus said.
The San Diego, California-based company's shares, which have gained 27 percent in the last one month, were up 8 percent at $3.71 on Wednesday afternoon on Nasdaq in heavy trading. ($1=.7634 Euro) (Reporting by Anand Basu in Bangalore; Editing by Unnikrishnan Nair)
RDNT(2.68) HOD, bouncing off bottom(100 day sma)
MMs sure do play games. My buy on NLTX was listed as a sale!
ACHN on the move!
BFR thank you. For now I think there are better plays posted on this board. I will keep this on my watchlist.
AEZS,AIS,CBRX,CORT,AMRN all jammin' today!
How does anybody feel about this article? Yes? No?
By Travis Hoium | More Articles
December 15, 2010
What: Amarin (Nasdaq: AMRN) shares jumped 10% in intraday trading today on very high volume.
So what: The biopharmaceutical company has already seen 5 million shares trade hands with two hours left in the trading day versus a daily average of 2 million shares. There was no new news from the company today, so it looks like the short squeeze is on.
Now what: There is some crazy price action today, and the stock, which didn't jump at the open, has seen two major spikes during the day. Last week, Foolish colleague Rich Duprey pointed out the spike in short interest in November and a spike like that often times leads to a short squeeze. But beware buying on a short squeeze as a stock can fall just as fast in coming days.
Does anybody know anything about OSUR other than what I can find on Yahoo. Institutions own 73%.
2,457,002. 3.5 days to cover.
PIP and SIGA seem to be moving in tandem. Both up over 7%.
NBIX and EXEL doing well today.
QCOR new all time high 15.57
WI Biker, MNKD is a beast. What a find!
AMRN highest pps since 11/30/10.(11 days)
DEPO, nice move up this morning!
$heff, thank you so much for all that you do for your members. I would not be as far ahead as I am without the knowledge you share with all of us. Please keep up the great work. This thanks also goes to every board member for your dd. It makes us all better investors.
Still holding my CAPS. I think this selloff is way over done. JMO
INHX- my biggest loss this year(24%). S#*t happens. Still had some great winners, am still up for the year and had a GREAT wedding and reception. Life is still good.
CAPS hasn't been this low (.40) since 2/24/09. This sucks!
Yes. Also heard good points. There are conflicting news reports out. Some reports say they were favorable treatment differences observed for KEY secondary pain endpoints. Other reports say shingles drug fails in mid-stage trial. It sounded more positive to me than negative. OB nailed it with "the sizzle got ahead of the steak". I'm still long INHX>
I'm sure a lot of us did, but I bought more while it was down. Profit taking, weak hands and kneejerk reaction to good news. I'll be patient. Same with INHX ah.
FV-100 works better than Valtrex for shingles. A very positive cc. I don't understand why it's trading down. Valtrex is a marketed drug and fv-100 works better. Some big pharma is going to partner on this eventually.
INHX trading halt. News pending.
CYTK 100,000 buy @ 2.29 ask.
Do you have a link for this info??
On a one minute chart CYTK is being accumulated in some large blocks. 395,000 @ 2.32 ia almost $1,000,000. Serious cash.
395,000 share block @ 2.32 when ask was 2.31 @ 12:37 pm. ??????
CORT having a nice morning.
The same thing happened to CYTK on 9/21/2010 when they announced this.
Press Release Source: Cytokinetics, Inc. On Tuesday September 21, 2010, 4:00 pm EDT
SOUTH SAN FRANCISCO, CA--(Marketwire - 09/21/10) - Cytokinetics, Incorporated (NASDAQ:CYTK - News) announced today that the company and its partner, Amgen Inc., plan to initiate a Phase IIb clinical trial of an intravenous formulation of omecamtiv mecarbil in hospitalized patients with acutely decompensated heart failure prior to initiating clinical trials of oral formulations of omecamtiv mecarbil.
This plan, which is subject to further discussions with regulatory authorities, is intended to align feedback received from regulatory authorities and is designed to provide a larger, placebo-controlled experience with omecamtiv mecarbil prior to proceeding to clinical trials of oral formulations of omecamtiv mecarbil in outpatients.
Cytokinetics expects to provide updated guidance on the anticipated timing of the initiation of these clinical trials following further discussions with both Amgen and regulatory authorities.
Amgen holds an exclusive, world-wide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.
Development Status of Omecamtiv Mecarbil (formerly CK-1827452)
Omecamtiv mecarbil, a novel cardiac muscle myosin activator, has been the subject of a clinical trials program comprised of multiple Phase I and Phase IIa trials. This program was designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetic profile of both intravenous and oral formulations of omecamtiv mecarbil for the potential treatment of heart failure across the continuum of care, in both hospital and outpatient settings. Two Phase IIa clinical trials of omecamtiv mecarbil from this program have been completed. In addition, Cytokinetics conducted five Phase I clinical trials of omecamtiv mecarbil in healthy subjects: a first-time-in-humans study evaluating an intravenous formulation, an oral bioavailability study evaluating both intravenous and oral formulations, and three studies of oral formulations: a drug-drug interaction study, a dose proportionality study and a study evaluating modified-release formulations. Data from each of these trials have been reported previously.
DEPO, quietly moving up again.
Right there with you. Bought more @ 2.34.
Perhaps a good time to buy more while it's down.
Thanks again.
Thanks Doc. Would that be the same with AMRN? 150,000 @ 5.82 @ 4:19 pm.
CORT, CYTK, DEPO and INHX all had big block buys on the close. Someone wanted to get in all of these!